Cargando…

Harnessing host innate immunity may combat acquired resistance to BRAFi

Detalles Bibliográficos
Autores principales:	Tan, Thomas, Pangigadde, Pradeepa, Sabbatino, Francesco, Favoino, Elvira, Orgiano, Laura, Ferrone, Soldano, Carbone, Ennio, Colucci, Francesco
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2014
Materias:	Oral Presentation
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4126229/ http://dx.doi.org/10.1186/1479-5876-12-S1-O10

Ejemplares similares

HLA class I downregulation is associated with enhanced NK‐cell killing of melanoma cells with acquired drug resistance to BRAF inhibitors
por: Sottile, Rosa, et al.
Publicado: (2015)

Melanoma: BRAFi Rechallenge
por: Kosmidis, Christoforos S., et al.
Publicado: (2023)

Acquired resistance to BRAFi reverses senescence-like phenotype in mutant BRAF melanoma
por: Krayem, Mohammad, et al.
Publicado: (2018)

The Role of Senescent Cells in Acquired Drug Resistance and Secondary Cancer in BRAFi-Treated Melanoma
por: Thompson, Elizabeth L., et al.
Publicado: (2021)

Grp94-specific monoclonal antibody to counteract BRAF inhibitor resistance in BRAF(V600E) melanoma
por: Sabbatino, F, et al.
Publicado: (2015)

Ipilimumab in the treatment of metastatic melanoma: management of adverse events
por: Della Vittoria Scarpati, Giuseppina, et al.
Publicado: (2014)

Therapy for BRAFi-Resistant Melanomas: Is WNT5A the Answer?
por: Prasad, Chandra Prakash, et al.
Publicado: (2015)

Changes in the Transcriptome and Chromatin Landscape in BRAFi-Resistant Melanoma Cells
por: Reddi, Kiran Kumar, et al.
Publicado: (2022)

NK cells blur the frontier between innate and acquired immunity
por: Terrazzano, Giuseppe, et al.
Publicado: (2013)

Resistance to anti-PD-1-based immunotherapy in basal cell carcinoma: a case report and review of the literature
por: Sabbatino, Francesco, et al.
Publicado: (2018)

Proteomics and Phosphoproteomics Profiling of Drug-Addicted BRAFi-Resistant Melanoma Cells
por: Li, Bohui, et al.
Publicado: (2021)

Analysis of T and NK cells immune response in Ipilimumab treated Melanoma patients
por: Tallerico, Rossana, et al.
Publicado: (2015)

Effect of ABT-888 on the apoptosis, motility and invasiveness of BRAFi-resistant melanoma cells
por: Fratangelo, Federica, et al.
Publicado: (2018)

The AhR‐SRC axis as a therapeutic vulnerability in BRAFi‐resistant melanoma
por: Paris, Anaïs, et al.
Publicado: (2022)

Chondroitin sulfate proteoglycan 4 expression in chondrosarcoma: A potential target for antibody-based immunotherapy
por: Nota, Sjoerd P. F. T., et al.
Publicado: (2022)

Proteasome Inhibitors: Harnessing Proteostasis to Combat Disease
por: Sherman, David J., et al.
Publicado: (2020)

Harnessing RKIP to Combat Heart Disease and Cancer
por: Lorenz, Kristina, et al.
Publicado: (2022)

Combatting renal ciliopathies
por: Giles, RH
Publicado: (2012)

Rat embryonic fibroblasts immortalized by MRPS18-2 protein are target for NK-cells
por: Mushtaq, Muhammad, et al.
Publicado: (2017)

Revealing cancer initiating cells in metastatic melanomas by harnessing the host′s anti tumor humoral immune mechanisms
por: Kotlan, Beatrix, et al.
Publicado: (2014)

miR-514a regulates the tumour suppressor NF1 and modulates BRAFi sensitivity in melanoma
por: Stark, Mitchell S., et al.
Publicado: (2015)

Anti-tumor antibody profile analysis to harness the potentials of B cells in melanomas and the natural humoral immune response
por: Kotlan, Beatrix, et al.
Publicado: (2013)

Harnessing the CRISPR-Cas Systems to Combat Antimicrobial Resistance
por: Duan, Cheng, et al.
Publicado: (2021)

Rewarding patient-directed research: Excellence in Translational Medicine Award
por: Brander, Christian, et al.
Publicado: (2006)

Reconsidering the policy options to combat obesity
por: Ferguson, Christine
Publicado: (2012)

Harnessing RNA interference to prevent or treat HSV-2 and HIV
por: Lieberman, Judy
Publicado: (2006)

Harnessing endogenous pathways and metabolites to treat or prevent neurodegenerative disease
por: Golde, Todd E, et al.
Publicado: (2013)

Enrichment of KIR+CD57+ highly cytotoxic NK cells in sentinel lymph nodes of melanoma patients
por: Ali, Talib Hassan, et al.
Publicado: (2014)

Harnessing retinal phagocytes to combat pathological neovascularization in ischemic retinopathies?
por: Klotzsche-von Ameln, Anne, et al.
Publicado: (2022)

PDGFRα up-regulation mediated by sonic hedgehog pathway activation leads to BRAF inhibitor resistance in melanoma cells with BRAF mutation
por: Sabbatino, Francesco, et al.
Publicado: (2014)

High TIL, HLA, and Immune Checkpoint Expression in Conventional High-Grade and Dedifferentiated Chondrosarcoma and Poor Clinical Course of the Disease
por: Nota, Sjoerd P. F. T., et al.
Publicado: (2021)

ADAM12-L confers acquired 5-fluorouracil resistance in breast cancer cells
por: Wang, Xuedong, et al.
Publicado: (2017)

Enrichment of CD56(dim)KIR+CD57+ highly cytotoxic NK cells in tumor infiltrated lymph nodes of melanoma patients
por: Ali, Talib Hassan, et al.
Publicado: (2014)

A promising new therapy may assist efforts to combat ICU-acquired weakness
por: Bain, Sarah, et al.
Publicado: (2014)

Harnessing Finger Millet to Combat Calcium Deficiency in Humans: Challenges and Prospects
por: Puranik, Swati, et al.
Publicado: (2017)

Harnessing CRISPR-Cas to Combat COVID-19: From Diagnostics to Therapeutics
por: Chan, Kok Gan, et al.
Publicado: (2021)

Lost in Translation: Obstacles to Translational Medicine
por: Mankoff, Stacey P, et al.
Publicado: (2004)

Peritumoral Immune Infiltrate as a Prognostic Biomarker in Thin Melanoma
por: Sabbatino, Francesco, et al.
Publicado: (2020)

Harnessing the non-specific immunogenic effects of available vaccines to combat COVID-19
por: Mosaddeghi, Pouria, et al.
Publicado: (2020)

OralOpioids: Harnessing R Programming and Data Science to Combat Opioid Misuse
por: Banerjee, Ankona, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_u7haq489q446sbf0llv4425g40